Drug Profile


Alternative Names: CAR NKG2D; CAR-T NKG2D; CAR-T NKR-2; CM-CS-1; CYAD-01; NKR 2 T-cell; NKR-2; NKR-2 T-cell immunotherapy; NKR-T cells

Latest Information Update: 20 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dartmouth College
  • Developer Celyad; Dana-Farber Cancer Institute
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Haematological malignancies; Multiple myeloma; Solid tumours
  • Phase I Colorectal cancer

Most Recent Events

  • 15 Mar 2018 Celyad in collaboration with Novella Clinical plans the DEPLETHINK phase I trial for Acute myeloid leukemia and Myelodysplastic-syndromes in May 2018 , (NCT03466320)
  • 11 Oct 2017 Celyad initiates enrolment in the LINK phase I trial for Colorectal cancer (Late-stage disease) in Belgium (NCT03370198)
  • 03 Oct 2017 Adverse events data from the phase I/II THINK trial in Solid tumours released by Celyad
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top